Return-path: <>
Envelope-to: lbaez@edenetsa.com
Delivery-date: Mon, 03 Nov 2014 18:36:52 -0400
Received: from [71.28.69.19] (port=64779 helo=173.188.202.88)
	by host8.dnns.net with smtp (Exim 4.82)
	id 1XlQF2-0005gc-0a
	for lbaez@edenetsa.com; Mon, 03 Nov 2014 18:36:52 -0400
Received: from unknown (HELO localhost) (sotiris@e-technik.uni-rostock.de@161.180.162.42)
	by 71.28.69.19 with ESMTPA; Mon, 3 Nov 2014 17:38:54 -0500
From: sotiris@e-technik.uni-rostock.de
To: lbaez@edenetsa.com
Subject: It get ready for another exciting week

"Oncolytics Biotech" Biotechnology Firm focuses on the development of 
oncolytic viruses for their further use in the treatment of various forms of 
cancer. The top company's drug - "REOLYSIN" - is currently in the last stage 
of clinical testings against cancer of head and neck. The medicine's action 
is based on the reovirus (Respiratory Enteric Orphan virus) ability to 
determine and "infect" the cells with the mutated RAS gene. After mutation 
the gene transforms an ordinary cell into a cancer one. "REOLYSIN", developed 
by the Canadian company "Oncolytics Biotech Inc", not only detects the cancer 
cells with the mutated gene, but also kills them. Given that 2/3 of tumors 
have cells with the mutated RAS gene, it is hoped that complicated and even 
propagating tumors might be cured without radiation and chemotherapy.

According to recent data, the use of the reovirus drug in conjunction with 
chemotherapeutic treatment enlarges the ratio of fortunate result for the 
treatment of the head and neck cancer up to 74%.

"Oncolytics Biotech Inc (ONCY)" Company's shares are available on NASDAQ 
since 2001, Market Cap 72.36M, rated by Zacks "Strong Buy". As of the end of 
trading on 03/11/2014, the stock price was $0.88, which is a good entry point 
for investing in new emerging technologies.

Let us recall that "Oncolytics Biotech Inc" Company was established in 
Calgary in 1998 in response to discoveries made on the oncolytic potential of 
reovirus at the University of Calgary during the 1990s. From 1999 to 2000 the 
enterprise transitioned from private to public ownership. 

The firm was granted its first Canadian patent in August 2000, and currently 
owns more than 200 patents across the globe, including 38 U.S. and 11 
Canadian patents.